Symbols / LEXX Stock $0.62 +2.38% Lexaria Bioscience Corp.

Healthcare • Biotechnology • Canada • NCM
LEXX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Richard C. Christopher
Exch · Country NCM · Canada
Market Cap 15.28M
Enterprise Value 9.71M
Income -9.53M
Sales 368.00K
FCF (ttm) -5.93M
Book/sh 0.27
Cash/sh 0.21
Employees 7
Insider 10d —
IPO Jan 12, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.58
PEG —
P/S 41.51
P/B 2.33
P/C —
EV/EBITDA -1.06
EV/Sales 26.38
Quick Ratio 24.74
Current Ratio 26.88
Debt/Eq 1.52
LT Debt/Eq —
EPS (ttm) -0.47
EPS next Y -0.39
EPS Growth —
Revenue Growth -88.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-13
Earnings (prior) 2026-04-13
ROA -75.98%
ROE -147.07%
ROIC —
Gross Margin 100.00%
Oper. Margin -72.60%
Profit Margin 0.00%
Shs Outstand 24.79M
Shs Float 23.44M
Insider Own 5.74%
Instit Own 6.01%
Short Float 1.60%
Short Ratio 1.96
Short Interest 381.89K
52W High 1.55
vs 52W High -60.24%
52W Low 0.46
vs 52W Low 33.98%
Beta 0.36
Impl. Vol. —
Rel Volume 0.30
Avg Volume 169.37K
Volume 50.58K
Target (mean) $3.75
Tgt Median $3.75
Tgt Low $1.50
Tgt High $6.00
# Analysts 2
Recom None
Prev Close $0.60
Price $0.62
Change 2.38%
About

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.75
Mean price target
2. Current target
$0.62
Latest analyst target
3. DCF / Fair value
$-4.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.62
Low
$1.50
High
$6.00
Mean
$3.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-26 main HC Wainwright & Co. Buy → Buy $2
2025-07-29 main HC Wainwright & Co. Buy → Buy $4
2025-07-01 main HC Wainwright & Co. Buy → Buy $5
2025-01-24 main HC Wainwright & Co. Buy → Buy $7
2024-12-02 reit HC Wainwright & Co. Buy → Buy $10
2024-11-25 reit HC Wainwright & Co. Buy → Buy $10
2024-07-18 reit HC Wainwright & Co. Buy → Buy $10
2024-07-10 init HC Wainwright & Co. — → Buy $10
2024-03-05 main Maxim Group Buy → Buy $12
2023-07-21 init Maxim Group — → Buy $2
News
RSS: Latest LEXX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 BUNKA CHRISTOPHER ANDREW Director — 100,000 $0.00 $0
2025-07-30 BUNKA CHRISTOPHER ANDREW Director — 27,500 $0.91 $25,241
2025-07-29 CHRISTOPHER RICHARD C Chief Executive Officer — 15,000 $0.91 $13,641
2025-07-29 DOCHERTY JOHN MARTIN President — 5,376 $0.93 $4,989
2025-07-29 MCKECHNIE WILLIAM EDWARD Director — 5,000 $0.91 $4,532
2025-07-29 CARLE VANESSA Officer — 750 $0.91 $682
2025-01-07 BUNKA CHRISTOPHER ANDREW Director — 100,000 $0.00 $0
2024-12-03 CHRISTOPHER RICHARD C Chief Executive Officer — 50,000 $2.24 $118,392
2024-08-12 TURKEL CATHERINE C Director — 1,600 $3.13 $5,008
2024-07-31 CARLE VANESSA Officer — 2,567 $4.00 $10,268
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Total Revenue
0.71
+52.05%
0.46
+105.24%
0.23
-11.43%
0.26
Operating Revenue
0.71
+52.34%
0.46
+142.65%
0.19
+13.67%
0.17
Cost Of Revenue
0.00
-43.59%
0.00
-84.69%
0.03
-56.15%
0.07
Reconciled Cost Of Revenue
0.00
-43.59%
0.00
-84.69%
0.03
-56.15%
0.07
Gross Profit
0.70
+53.05%
0.46
+135.97%
0.19
+6.08%
0.18
Operating Expense
12.58
+102.56%
6.21
-7.67%
6.73
-1.09%
6.80
Research And Development
8.24
+249.02%
2.36
-35.62%
3.67
+98.99%
1.84
Selling General And Administration
4.35
+12.80%
3.85
+25.80%
3.06
-38.26%
4.96
General And Administrative Expense
4.35
+12.80%
3.85
+25.80%
3.06
-38.26%
4.96
Other Gand A
4.35
+12.80%
3.85
+25.80%
3.06
-38.26%
4.96
Total Expenses
12.59
+102.44%
6.22
-8.03%
6.76
-1.66%
6.87
Operating Income
-11.88
-106.51%
-5.75
+11.95%
-6.53
+1.28%
-6.62
Total Operating Income As Reported
-11.88
-106.51%
-5.75
+11.95%
-6.53
+1.28%
-6.62
EBITDA
-11.79
-107.73%
-5.68
+11.14%
-6.39
+1.96%
-6.52
Normalized EBITDA
-11.76
-109.72%
-5.61
+9.08%
-6.17
-7.22%
-5.75
Reconciled Depreciation
0.09
+15.33%
0.08
-47.62%
0.15
+41.55%
0.10
EBIT
-11.88
-106.51%
-5.75
+11.95%
-6.53
+1.28%
-6.62
Total Unusual Items
-0.03
+51.72%
-0.07
+68.50%
-0.22
+71.01%
-0.76
Total Unusual Items Excluding Goodwill
-0.03
+51.72%
-0.07
+68.50%
-0.22
+71.01%
-0.76
Special Income Charges
—
—
—
0.00
Net Income
-11.90
-105.37%
-5.80
+13.05%
-6.66
+8.31%
-7.27
Pretax Income
-11.91
-105.06%
-5.81
+13.47%
-6.71
+9.09%
-7.38
Net Non Operating Interest Income Expense
0.00
-78.92%
0.01
-66.87%
0.04
0.00
Net Interest Income
0.00
-78.92%
0.01
-66.87%
0.04
0.00
Interest Income Non Operating
0.00
-78.92%
0.01
-66.87%
0.04
0.00
Interest Income
0.00
-78.92%
0.01
-66.87%
0.04
0.00
Other Income Expense
-0.03
+51.72%
-0.07
+68.50%
-0.22
+71.01%
-0.76
Gain On Sale Of Security
-0.03
+51.72%
-0.07
+68.50%
-0.22
+71.01%
-0.76
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.91
-105.06%
-5.81
+13.47%
-6.71
+9.09%
-7.38
Net Income From Continuing Operation Net Minority Interest
-11.90
-105.37%
-5.80
+13.05%
-6.66
+8.31%
-7.27
Net Income From Continuing And Discontinued Operation
-11.90
-105.37%
-5.80
+13.05%
-6.66
+8.31%
-7.27
Net Income Continuous Operations
-11.91
-105.06%
-5.81
+13.47%
-6.71
+9.09%
-7.38
Net Income Discontinuous Operations
—
—
—
0.00
Minority Interests
0.01
-27.92%
0.01
-72.06%
0.05
-58.34%
0.11
Normalized Income
-11.87
-107.29%
-5.73
+11.14%
-6.44
+0.95%
-6.50
Net Income Common Stockholders
-11.90
-105.37%
-5.80
+13.05%
-6.66
+8.31%
-7.27
Diluted EPS
-0.66
-40.43%
-0.47
+53.47%
-1.01
+18.55%
-1.24
Basic EPS
-0.66
-40.43%
-0.47
+53.47%
-1.01
+18.55%
-1.24
Basic Average Shares
18.00
+45.34%
12.38
+87.24%
6.61
+12.38%
5.89
Diluted Average Shares
18.00
+45.34%
12.38
+87.24%
6.61
+12.38%
5.89
Diluted NI Availto Com Stockholders
-11.90
-105.37%
-5.80
+13.05%
-6.66
+8.31%
-7.27
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Total Assets
4.18
-52.92%
8.87
+187.54%
3.08
-60.63%
7.83
Current Assets
3.47
-56.09%
7.90
+267.14%
2.15
-69.17%
6.98
Cash Cash Equivalents And Short Term Investments
1.97
-69.99%
6.56
+343.63%
1.48
-76.01%
6.16
Cash And Cash Equivalents
1.80
-72.27%
6.50
+380.72%
1.35
-76.74%
5.81
Cash Financial
1.80
-72.27%
6.50
+380.72%
1.35
-76.74%
5.81
Other Short Term Investments
0.17
+196.31%
0.06
-55.58%
0.13
-63.83%
0.35
Receivables
0.37
+138.45%
0.15
+21.94%
0.13
-37.22%
0.20
Accounts Receivable
—
—
0.05
-39.58%
0.08
Other Receivables
0.17
+107.14%
0.08
+240.98%
0.02
-33.86%
0.04
Taxes Receivable
0.19
+175.78%
0.07
-30.94%
0.10
+21.26%
0.08
Inventory
—
—
0.00
-100.00%
0.04
Raw Materials
—
—
0.00
-100.00%
0.04
Prepaid Assets
1.13
-4.66%
1.19
+117.24%
0.55
-5.20%
0.58
Total Non Current Assets
0.71
-27.12%
0.97
+3.97%
0.93
+8.92%
0.86
Net PPE
0.33
-14.02%
0.39
-7.60%
0.42
+14.58%
0.37
Gross PPE
0.90
-0.37%
0.91
+1.16%
0.90
+19.90%
0.75
Accumulated Depreciation
-0.57
-9.90%
-0.52
-8.93%
-0.48
-25.05%
-0.38
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Other Properties
0.54
-0.62%
0.55
+1.95%
0.53
+38.55%
0.39
Leases
0.26
+0.00%
0.26
+0.00%
0.26
+0.00%
0.26
Goodwill And Other Intangible Assets
0.31
-40.42%
0.52
+11.68%
0.46
-5.29%
0.49
Other Intangible Assets
0.31
-40.42%
0.52
+11.68%
0.46
-5.29%
0.49
Non Current Accounts Receivable
0.06
+0.69%
0.06
+30.92%
0.05
—
Total Liabilities Net Minority Interest
1.57
+30.08%
1.21
+199.26%
0.40
+100.51%
0.20
Current Liabilities
1.49
+35.84%
1.10
+310.64%
0.27
+37.98%
0.19
Payables And Accrued Expenses
1.46
+37.19%
1.07
+344.45%
0.24
+58.43%
0.15
Payables
1.46
+37.19%
1.07
+344.45%
0.24
+58.43%
0.15
Accounts Payable
1.37
+29.04%
1.06
+370.09%
0.23
+87.30%
0.12
Other Payable
0.08
—
—
0.06
Total Tax Payable
0.02
+152.18%
0.01
-42.78%
0.01
-52.39%
0.03
Income Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
0.03
+8.45%
0.03
+0.91%
0.03
-34.74%
0.04
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
0.03
+8.45%
0.03
+0.91%
0.03
-34.74%
0.04
Current Deferred Liabilities
0.00
-100.00%
0.00
0.00
—
Current Deferred Revenue
0.00
-100.00%
0.00
0.00
—
Total Non Current Liabilities Net Minority Interest
0.08
-27.82%
0.11
-19.72%
0.14
+1739.93%
0.01
Long Term Debt And Capital Lease Obligation
0.08
-27.82%
0.11
-19.72%
0.14
+1739.93%
0.01
Long Term Capital Lease Obligation
0.08
-27.82%
0.11
-19.72%
0.14
+1739.93%
0.01
Stockholders Equity
2.99
-62.80%
8.04
+164.00%
3.04
-61.70%
7.95
Common Stock Equity
2.99
-62.80%
8.04
+164.00%
3.04
-61.70%
7.95
Capital Stock
0.02
+23.71%
0.02
+95.40%
0.01
+35.96%
0.01
Common Stock
0.02
+23.71%
0.02
+95.40%
0.01
+35.96%
0.01
Share Issued
19.56
+23.71%
15.81
+95.39%
8.09
+35.97%
5.95
Ordinary Shares Number
19.56
+23.71%
15.81
+95.39%
8.09
+35.97%
5.95
Additional Paid In Capital
66.50
+11.58%
59.60
+22.13%
48.80
+3.74%
47.04
Retained Earnings
-63.46
-23.08%
-51.56
-12.66%
-45.76
-17.05%
-39.10
Gains Losses Not Affecting Retained Earnings
-0.07
-254.94%
-0.02
0.00
—
Minority Interest
-0.39
-2.54%
-0.38
-3.66%
-0.36
-15.05%
-0.32
Other Equity Adjustments
-0.07
-254.94%
-0.02
—
—
Total Equity Gross Minority Interest
2.60
-66.02%
7.66
+185.78%
2.68
-64.89%
7.63
Total Capitalization
2.99
-62.80%
8.04
+164.00%
3.04
-61.70%
7.95
Working Capital
1.97
-70.95%
6.80
+260.96%
1.88
-72.23%
6.78
Invested Capital
2.99
-62.80%
8.04
+164.00%
3.04
-61.70%
7.95
Total Debt
0.11
-20.42%
0.14
-16.22%
0.16
+228.01%
0.05
Capital Lease Obligations
0.11
-20.42%
0.14
-16.22%
0.16
+228.01%
0.05
Net Tangible Assets
2.68
-64.34%
7.52
+191.29%
2.58
-65.40%
7.46
Tangible Book Value
2.68
-64.34%
7.52
+191.29%
2.58
-65.40%
7.46
Dueto Related Parties Current
—
—
—
—
Line Item Trend 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Operating Cash Flow
-10.45
-110.74%
-4.96
+15.68%
-5.88
-20.53%
-4.88
Cash Flow From Continuing Operating Activities
-10.45
-110.74%
-4.96
+15.68%
-5.88
-20.53%
-4.88
Net Income From Continuing Operations
-11.91
-105.06%
-5.81
+13.47%
-6.71
+9.09%
-7.38
Depreciation Amortization Depletion
0.09
+15.33%
0.08
-47.62%
0.15
+41.55%
0.10
Depreciation
—
—
—
0.14
Depreciation And Amortization
0.09
+15.33%
0.08
-47.62%
0.15
+41.55%
0.10
Other Non Cash Items
0.04
-5.60%
0.04
-10.31%
0.04
-96.48%
1.24
Stock Based Compensation
0.86
+74.61%
0.49
+188.90%
0.17
-77.36%
0.75
Asset Impairment Charge
0.25
+277.10%
0.07
-38.56%
0.11
0.00
Operating Gains Losses
—
—
—
-0.01
Gain Loss On Investment Securities
—
—
—
—
Unrealized Gain Loss On Investment Securities
0.03
-51.72%
0.07
-68.50%
0.22
-71.01%
0.76
Change In Working Capital
0.20
+83.54%
0.11
-25.62%
0.14
+140.76%
-0.35
Change In Receivables
-0.21
-323.83%
-0.05
-290.54%
0.03
+119.30%
-0.14
Changes In Account Receivables
-0.21
-501.62%
-0.04
-233.96%
0.03
+119.30%
-0.14
Change In Inventory
—
0.00
-100.00%
0.04
+2276.30%
-0.00
Change In Prepaid Assets
0.06
+108.63%
-0.64
-2238.35%
0.03
+111.64%
-0.26
Change In Payables And Accrued Expense
0.40
-52.01%
0.83
+833.95%
0.09
+94.48%
0.05
Change In Payable
—
0.83
+833.95%
0.09
+94.48%
0.05
Change In Account Payable
—
0.83
+833.95%
0.09
+74.45%
0.05
Change In Other Working Capital
-0.00
-200.00%
0.00
—
—
Change In Other Current Liabilities
-0.04
-11.48%
-0.03
+25.75%
-0.04
0.00
Investing Cash Flow
-0.24
-28.85%
-0.19
-11.20%
-0.17
+6.11%
-0.18
Cash Flow From Continuing Investing Activities
-0.24
-28.85%
-0.19
-11.20%
-0.17
+6.11%
-0.18
Net PPE Purchase And Sale
-0.02
+42.70%
-0.04
-27.46%
-0.03
+31.40%
-0.05
Purchase Of PPE
-0.02
+42.70%
-0.04
-27.46%
-0.03
+31.40%
-0.05
Capital Expenditure
-0.10
+47.11%
-0.19
-11.20%
-0.17
+6.11%
-0.18
Net Investment Purchase And Sale
-0.14
0.00
—
—
Sale Of Investment
—
—
—
—
Net Intangibles Purchase And Sale
-0.08
+48.41%
-0.15
-7.16%
-0.14
-3.36%
-0.13
Purchase Of Intangibles
-0.08
+48.41%
-0.15
—
-0.13
Net Other Investing Changes
—
—
—
-0.05
Financing Cash Flow
6.05
-41.39%
10.32
+548.86%
1.59
+3664.42%
-0.04
Cash Flow From Continuing Financing Activities
6.05
-41.39%
10.32
+548.86%
1.59
+3664.42%
-0.04
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.04
Repayment Of Debt
—
—
0.00
+100.00%
-0.04
Long Term Debt Payments
—
—
0.00
+100.00%
-0.04
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.04
Net Common Stock Issuance
6.05
+43.66%
4.21
+164.74%
1.59
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
6.11
0.00
0.00
Changes In Cash
-4.65
-189.93%
5.17
+215.84%
-4.46
+12.61%
-5.10
Effect Of Exchange Rate Changes
-0.05
-154.94%
-0.02
0.00
—
Beginning Cash Position
6.50
+380.72%
1.35
-76.74%
5.81
-46.75%
10.92
End Cash Position
1.80
-72.27%
6.50
+380.72%
1.35
-76.74%
5.81
Free Cash Flow
-10.55
-104.95%
-5.15
+14.93%
-6.05
-19.58%
-5.06
Income Tax Paid Supplemental Data
—
0.01
+22.25%
0.01
+71.77%
0.00
Common Stock Issuance
6.05
+43.66%
4.21
+164.74%
1.59
0.00
Issuance Of Capital Stock
6.05
+43.66%
4.21
+164.74%
1.59
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category